drugset / Trial / NCT00731549
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
Phase 3
Completed
1081 enrolled
Otsuka Pharmaceutical Development & Commercialization, Inc.
Covance · collab
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the overall effectiveness of aripiprazole intramuscular (IM) depot as maintenance treatment in patients with schizophrenia.
Timeline
- Start
- 2008-12
- Primary completion
- 2013-11
- Completion
- 2013-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aripiprazole | Other / unclassified | 300 mg | Intramuscular |
| Subject | Aripiprazole | Other / unclassified | 400 mg | Intramuscular |